A2073 is a flavonoid derivative that inhibits the proliferation of erythroleukemia cells by inducing cell cycle arrest and suppressing the MAPK, NF-κB, and PI3K signaling pathways. It forms stable interactions with cell cycle-related proteins (CDK1, CCNA2, PRIM1). In a zebrafish xenograft tumor model, A2073 demonstrates significant anti-tumor cell proliferation activity while maintaining low toxicity. A2073 is suitable for research in acute erythroleukemia.

A2073, at concentrations of 25-100 nM over 24-72 hours, effectively inhibits the proliferation of HEL and K562 cells in a dose- and time-dependent manner, with IC50 values of 55.02 nM for HEL and 77.07 nM for K562. This compound decreases the number of HEL cells without significantly increasing apoptosis, induces erythroid differentiation in HEL cells (indicated by increased CD71 expression), and causes cell cycle arrest while downregulating key cell cycle regulatory proteins. A2073 also downregulates essential proteins in the MAPK (RAS, RAF, MAPK, MEK, PI3K-AKT (PI3K, AKT)) and NF-κB (p-NF-κB, p-IκBα) signaling pathways after 48 hours of exposure. Additionally, it forms stable interactions with cell cycle-related proteins (CDK1, CCNA2, PRIM1).

A2073 (25-100 nM, 1-5 days) effectively inhibits the proliferation of HEL cells in a zebrafish xenograft tumor model.